Genomes and Genes
Summary: Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.
Publications265 found, 100 shown here
- Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyGregory Feldman
S Carolina Pharmaceutical Research, Spartanburg, SC, USA
BMC Pulm Med 10:11. 2010..This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD...
- Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonDonald A Mahler
Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
Thorax 67:781-8. 2012..The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone...
- Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue
University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
Am J Respir Crit Care Med 182:155-62. 2010..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
- Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDRonald Dahl
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Thorax 65:473-9. 2010..In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year...
- Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonO Kornmann
Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
Eur Respir J 37:273-9. 2011..Indacaterol should prove a useful additional treatment for patients with COPD...
- Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPDR Buhl
Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, Mainz, D 55131, Germany
Eur Respir J 38:797-803. 2011..Both bronchodilators demonstrated spirometric efficacy. The two treatments were well tolerated with similar adverse event profiles. Compared with tiotropium, indacaterol provided significantly greater improvements in clinical outcomes...
- Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisShannon Cope
Mapi Consultancy, Boston, MA, USA
BMC Pulm Med 12:29. 2012....
- Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic reviewGustavo J Rodrigo
Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 11300 Uruguay
Chest 142:1104-10. 2012..Bronchodilators are central to the symptomatic management of patients with COPD.Previous data have shown that inhaled indacaterol improved numerous clinical outcomes over placebo...
- Effect of indacaterol on exercise endurance and lung hyperinflation in COPDDenis E O'Donnell
Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
Respir Med 105:1030-6. 2011..This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD...
- Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman
Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
Chest 140:68-75. 2011..Indacaterol is an inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily dosing in patients with COPD...
- Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patientsR M Mroz
Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland
Adv Exp Med Biol 756:23-8. 2013..The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients...
- Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesEdward M Kerwin
Clinical Research Institute of Southern Oregon PC, Medford, Oregon 97504, USA
Clin Ther 33:1974-84. 2011....
- QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseJan A van Noord
Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
Thorax 65:1086-91. 2010....
- Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyStephanie Korn
Pulmonary Department, Mainz University Hospital, Mainz, Germany
Respir Med 105:719-26. 2011..Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of COPD...
- Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard
Novartis Pharma AG, Basel, Switzerland
Respir Res 12:54. 2011..We considered alternative methods of analysis...
- Safety of indacaterol in the treatment of patients with COPDJames F Donohue
University of North Carolina, Chapel Hill, NC 27599, USA
Int J Chron Obstruct Pulmon Dis 6:477-92. 2011..Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2)-agonist for chronic obstructive pulmonary disease (COPD)...
- Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonistDiane M Ignar
Metabolic Diseases Department, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
J Pharmacol Exp Ther 339:24-34. 2011..In conclusion, GSK1521498 is a potent, MOR-selective inverse agonist that modulates the hedonic aspects of ingestion and, therefore, could represent a pharmacological treatment for obesity and binge-eating disorders...
- Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonShannon Cope
Mapi Consultancy, Boston, MA 02114, USA
Value Health 15:524-33. 2012..Indacaterol trial evidence was synthesized to provide coherent estimates of indacaterol 150 μg and indacaterol 300 μg relative to formoterol, salmeterol, and tiotropium...
- Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humansE A Rabiner
GSK Clinical Imaging Centre, Imperial College London, Hammersmith Hospital, London, UK
Mol Psychiatry 16:826-35, 785. 2011..Pharmacological differentiation of these molecules suggests that they may have different therapeutic profiles for treatment of overeating and other disorders of compulsive consumption...
- Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eatingChiara Giuliano
Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge, UK
Neuropsychopharmacology 37:2643-52. 2012....
- Indacaterol once-daily is equally effective dosed in the evening or morning in COPDH Magnussen
Pulmonary Research Institute, Hospital Grosshansdorf, Grosshansdorf, Germany
Respir Med 104:1869-76. 2010..05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening...
- Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisPaul W Jones
Division of Clinical Science, St George s, University of London, London, UK
Respir Res 12:161. 2011..We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes...
- Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled studyMasaharu Kinoshita
Nagata Hospital, Fukuoka, Japan
Respirology 17:379-89. 2012..This study was primarily designed to obtain the regulatory approval of indacaterol in Japan...
- Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropiumAndrea Rossi
Unità Operativa Complessa di Pneumologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
Respir Med 106:84-90. 2012..Evidence has been provided that high-dose indacaterol (300 μg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD)...
- A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADB Winblad
Karolinska Institutet, Alzheimer s Disease Research Center, Division of Geriatric Medicine, Huddinge Hospital B, Stockholm, Sweden
Neurology 57:489-95. 2001..To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD...
- Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier
Novartis Pharmaceuticals Inc, One Health Plaza, East Hanover, NJ 07936 1080, USA
Respir Res 11:135. 2010..This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with moderate-to-severe COPD...
- Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsBoudewijn Van de Maele
AZ Sint Jan Brugge Oostende AV, Campus H Serruys, Oostende, Belgium
COPD 7:418-27. 2010..Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo...
- Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPDKai Michael Beeh
insaf Respiratory Research Institute, D 65187 Wiesbaden, Germany
COPD 8:340-5. 2011..In conclusion, indacaterol 300 μg administered once-daily showed a clinically relevant increase in IC after 14 days of treatment, reflecting a reduction in dynamic hyperinflation...
- Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb modelYoshihiko Kakinuma
Department of Cardiovascular Control, Kochi Medical School, Nankoku, Kochi 783 8505, Japan
J Mol Cell Cardiol 48:680-93. 2010..The present study concludes that donepezil can act as a therapeutic tool to accelerate angiogenesis in cardiovascular disease patients...
- Efficacy of indacaterol in the treatment of patients with COPDPaul W Jones
Division of Clinical Sciences, St George s University of London, London, UK
Prim Care Respir J 20:380-8. 2011..The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD...
- Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysisJ Wang
Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
J Clin Pharm Ther 37:204-11. 2012..However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations...
- Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonistPradeep J Nathan
Clinical Unit Cambridge, Cambridge, UK
J Clin Pharmacol 52:464-74. 2012..These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption...
- Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studiesMark H Gotfried
Pulmonary Associates PA, Phoenix, AZ 85006, USA
COPD 9:629-36. 2012..Treatment with indacaterol 75 μg may provide useful improvements in patient-reported outcomes in patients with moderate-to-severe COPD...
- Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPDHeinrich Worth
Medical Department I, Klinikum Fürth, Jakob Henle Str 1, D 90766 Fürth, Germany
Respir Med 105:571-9. 2011..As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting β(2)-agonist for COPD...
- Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolGregory J Feldman
S Carolina Pharmaceutical Research, Alliance Biomedical Group International, Spartanburg, SC 29303, USA
Int J Chron Obstruct Pulmon Dis 8:89-96. 2013..As there is no cure for COPD, a major goal of treatment and of research into new therapies is to improve HR-QOL in COPD patients...
- Comparative efficacy of indacaterol in chronic obstructive pulmonary diseaseMarcos Ribeiro
Asthma and Airway Centre, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Int J Chron Obstruct Pulmon Dis 7:145-52. 2012..It is likely that once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes in patients with COPD...
- Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneBeatrix Balint
Csongrád Megyei OnkormányzatMellkasi Betegségek Szakkórháza, Deszk, Hungary
Int J Chron Obstruct Pulmon Dis 5:311-8. 2010..indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease (COPD)...
- Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498Pradeep J Nathan
GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
J Clin Pharmacol 52:1456-67. 2012..These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498...
- Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysisShannon Cope
Mapi Consultancy, Boston, MA 02114, USA
Int J Chron Obstruct Pulmon Dis 7:415-20. 2012....
- Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled dataEugene R Bleecker
Center for Genomics and Personalized Medicine Research and Translational Medicine Institute, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
Int J Chron Obstruct Pulmon Dis 6:431-8. 2011..As indacaterol is the first once-daily β(2)-agonist to be developed, it is relevant to evaluate its bronchodilator efficacy, safety, and tolerability...
- Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPDKenneth R Chapman
Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
Int J Chron Obstruct Pulmon Dis 6:353-63. 2011..These are important factors for optimum dose delivery and successful COPD management...
- Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacyDavid G Wilkinson
Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
Drugs Aging 21:453-78. 2004....
- Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trialAkira Homma
Dementia Interventional Research Group, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Dement Geriatr Cogn Disord 25:399-407. 2008..A 24-week, randomized, parallel-group, double-blind placebo-controlled study was conducted to evaluate the efficacy and tolerability of donepezil in severe Alzheimer's disease (AD)...
- Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen
Mayo Clinic College of Medicine, Rochester, Minn, USA
N Engl J Med 352:2379-88. 2005..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind studyMartin R Farlow
Department of Neurology, Indiana University School of Medicine, Indianapolis, 46202, USA
Clin Ther 32:1234-51. 2010..We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor...
- Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysisShannon Cope
Mapi Values, Boston, MA, USA
Int J Chron Obstruct Pulmon Dis 6:329-44. 2011....
- Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in miceTakemi Handa
Department of Cardiovascular Control, Kochi Medical School, Nankoku, Japan
J Card Fail 15:805-11. 2009....
- Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityOrly Weinreb
Eve Topf Centre of Excellence for Neurodegenerative Diseases, Technion Rappaport Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
Prog Neurobiol 92:330-44. 2010..This paper will review the earlier and present studies in the development of rasagiline for treatment of PD and discuss its pharmacology and applicable mechanism of action...
- Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatmentCarina Wattmo
Department of Clinical Sciences, Clinical Memory Research Unit, Malmo, Lund University, Sweden
Alzheimer Dis Assoc Disord 25:63-72. 2011..AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome...
- Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic reviewDimitris Repantis
Department of Psychiatry, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany
Pharmacol Res 61:473-81. 2010..At the moment, the research that would support or oppose the use of acetylcholinesterase inhibitors and memantine for neuroenhancement by healthy individuals has not yet been performed...
- Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPeter J Barnes
Imperial College, London, UK
Pulm Pharmacol Ther 23:165-71. 2010..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialO Rascol
Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
Lancet 365:947-54. 2005..This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations...
- Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational studyAurelia Santoro
Department of Experimental Pathology, University of Bologna, Via S Giacomo 12, Bologna, Italy
CNS Drugs 24:163-76. 2010..g. health status and co-morbidities) associated with a complex disease such as AD in elderly people...
- Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neuronsYuki Takada
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
J Pharmacol Exp Ther 306:772-7. 2003..These results suggest that donepezil not only protects cortical neurons against glutamate neurotoxicity via alpha4beta2- and alpha7-nAChRs but also prevents apoptotic neuronal death...
- Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseRobert A Hauser
Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
Mov Disord 24:564-73. 2009..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
- Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer diseaseR S Doody
Department of Neurology, Baylor College of Medicine, 6550 Fannin Street, Suite 1801, Houston, TX 77030-3498, USA
Arch Neurol 58:427-33. 2001..CONCLUSIONS: Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages...
- Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical settingAsa K Wallin
Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
Dement Geriatr Cogn Disord 23:150-60. 2007..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
- Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairmentDanielle C Whitehair
Department of Neurosciences, University of California, San Diego, CA, USA
Alzheimers Dement 6:412-9. 2010..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)...
- Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary diseaseCharlotta Karner
Population Health Sciences and Education, St George s, University of London, London, UK
Cochrane Database Syst Rev 4:CD008989. 2012..However, the benefits and risks of combining tiotropium and long-acting beta(2)-agonists for the treatment of chronic obstructive pulmonary (COPD) disease are unclear...
- Profiling the effects of indacaterol on dyspnoea and health status in patients with COPDPaul W Jones
Division of Clinical Science, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
Respir Med 105:892-9. 2011..The aim of this paper is to assess the effect of indacaterol on dyspnoea and health status, using pooled study data to evaluate the relative efficacy of indacaterol and existing bronchodilators...
- Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantineRachelle S Doody
Baylor College of Medicine, Houston, TX 07730, USA
Dement Geriatr Cogn Disord 33:164-73. 2012..We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use...
- Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slicesRichard G Sturton
Novartis Pharma AG, WSJ 386 12 16, P O Box, CH 4002 Basel, Switzerland
J Pharmacol Exp Ther 324:270-5. 2008..Finally, using the human lung slice model, we have characterized indacaterol as a fast acting compound with a longer duration of action than salmeterol and formoterol...
- Kinetic analysis of the inhibition of phenylalanine ammonia-lyase by 2-aminoindan-2-phosphonic acid and other phenylalanine analoguesChristoph Appert
Institute of Plant Sciences, Federal Institute of Technology Zurich, CH 8092 Zurich, Switzerland
Phytochemistry 62:415-22. 2003..The carboxyl analogue of AIP, 2-aminoindan-2-carboxylic acid, served as a substrate of PAL-1 and was converted to indene-2-carboxylic acid...
- Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary diseaseKate McKeage
Adis, Auckland, New Zealand
Drugs 72:543-63. 2012..In conclusion, indacaterol provides a valuable option for the maintenance treatment of adults with COPD...
- Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterolJutta Beier
insaf Respiratory Research Institute, Wiesbaden, Germany
Int J Chron Obstruct Pulmon Dis 6:237-43. 2011..This review summarizes relevant clinical data for twice-daily β-2-agonists in COPD, and further focuses on novel data for once-daily indacaterol, including head-to-head comparison trials...
- Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRonald Dahl
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark Electronic address
Respir Med 107:1558-67. 2013..We investigated the safety and efficacy of QVA149 over 52 weeks...
- Delirium caused by donepezil: a case studyToshiro Kawashima
J Clin Psychiatry 63:250-1. 2002
- DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones
Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
Trials 10:57. 2009..The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil...
- Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezilHind T Hatoum
Center for Pharmacoeconomic Research, the University of Illinois at Chicago UIC, Chicago, IL, USA
J Med Econ 12:98-103. 2009..To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients...
- Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implicationsF Fagnani
CEMKA, Bourg la Reine, France
Dement Geriatr Cogn Disord 17:5-13. 2004..Overall, these data suggest that donepezil is a cost-effective treatment for mild to moderately impaired AD patients living in France...
- A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysisMartin R Farlow
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Curr Med Res Opin 26:263-9. 2010..To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving concomitant memantine...
- Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practiceHiroyuki Umegaki
Department of Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan
Int Psychogeriatr 20:800-6. 2008..In the current study we surveyed the discontinuation of donepezil, a cholinesterase inhibitor, for the treatment of Alzheimer's disease in a Japanese geriatric outpatient clinic in a university hospital...
- Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardiumYoshihiko Kakinuma
Department of Cardiovascular Control, Kochi Medical School, Nankoku, Japan
FEBS J 276:5111-25. 2009..Such an amplification system in cardiomyocytes may contribute to the beneficial effects of vagal stimulation on the ventricles...
- Cholinergic enhancement reduces spatial spread of visual responses in human early visual cortexMichael A Silver
School of Optometry, University of California, Berkeley, Berkeley, CA 94720, USA
Neuron 60:904-14. 2008..These findings demonstrate that acetylcholine regulates spatial integration in human visual cortex...
- A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's diseaseNorman R Relkin
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 428 East 72nd Street, Suite 500, New York, N Y 10021, USA
Dement Geriatr Cogn Disord 16:15-24. 2003..These results highlight donepezil as a safe and effective treatment for AD patients typically seen by community-based physicians...
- Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience studyMercè Boada-Rovira
Fundacio ACE, Barcelona, Spain
Drugs Aging 21:43-53. 2004..However, in order to control for confounding factors, some clinical trials of donepezil have excluded patients with comorbid illness and concomitant medication use...
- Indacaterol therapy in patients with COPD not receiving other maintenance treatmentMarc Decramer
Respiratory Division, University Hospitals, Chief Respiratory Division UZ Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
Respir Med 106:1706-14. 2012..Recent findings of rapid lung function decline in younger patients with moderate COPD severity suggest the need for effective early treatment...
- Donepezil preserves cognition and global function in patients with severe Alzheimer diseaseS E Black
Division of Neurology, Department of Medicine and Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
Neurology 69:459-69. 2007..To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)...
- Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatologyMarwan Sabbagh
The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, Sun City, Arizona, USA
BMC Neurol 11:21. 2011....
- Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive ratsS Eliash
Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel
J Neural Transm 108:909-23. 2001..The drugs were equipotent when they were given at a ratio of 1:2. The mechanism has yet to be elucidated. The differential effects of the drugs on blood pressure and MAO inhibition rule out either effect as the sole explanation...
- Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slicesJ P Spencer
Synaptic Plasticity and Neural Network Dynamics Discovery Performance Unit, Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, CM19 5AW, UK
Neuropharmacology 59:437-43. 2010..These data support the notion that it should be possible to find a more efficacious AChE inhibitor or an adjunctive approach, to provide a better therapeutic intervention in AD...
- An update on the use of indacaterol in patients with COPDNadia S Brienza
Respiratory Research Unit, Complexo Hospitalario Universitario and Instituto de Investigación Biomédica de A Coruña INIBIC, Spain
Ther Adv Respir Dis 5:29-40. 2011....
- The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's diseaseSarah Thompson
Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
Expert Opin Drug Saf 3:425-40. 2004..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
- Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failureYoshihisa Okazaki
Department of Artificial Organ Medicine, Division of Surgical Medicine, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
J Physiol Sci 60:67-74. 2010..These findings indicated that donepezil reproduced the anti-remodeling effect of electrical vagal stimulation. Further studies are warranted to evaluate the clinical usefulness of donepezil in heart failure...
- Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezilSandra Bond Chapman
The University of Texas at Dallas, USA
J Speech Lang Hear Res 47:1149-63. 2004..The fact that AD is a progressive brain disease should not preclude ameliorative treatment...
- Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe diseaseElias Schwam
Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY, USA schwae pfizer com
Dement Geriatr Cogn Disord 29:309-16. 2010....
- Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulationDenis Getsios
United BioSource Corporation, Lexington, MA02420, USA
Pharmacoeconomics 28:411-27. 2010..They also indicate that both benefits and savings may be greatest when treatment is started while patients are still in the mild stages of Alzheimer's disease...
- Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentialsG J LaHoste
Department of Psychology, University of New Orleans, New Orleans, Louisiana 70148, USA
J Neurosci 20:6666-71. 2000....
- Neuroprotective effect of rasagiline in a rodent model of Parkinson's diseaseF Blandini
Laboratory of Functional Neurochemistry, Neurological Institute C Mondino, 27100, Pavia, Italy
Exp Neurol 187:455-9. 2004..Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD)...
- Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in JapanMotohiro Nozawa
Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medial Center, Juntendo University School of Medicine, Tokyo, Japan
Psychogeriatrics 9:50-5. 2009..Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease...
- Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeysK Kaneda
Department of System Neuroscience, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, Fuchu, Tokyo 183 8526, Japan
Eur J Neurosci 22:3241-54. 2005....
- A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's diseaseGordon Wilcock
Department of Care of the Elderly, University of Bristol, Frenchay Hospital, Bristol, UK
Drugs Aging 20:777-89. 2003..To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer's disease...
- Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learnedSarah Lyle
Services for Older People, Shelton Hospital, Shrewsbury, UK
Dement Geriatr Cogn Disord 25:226-31. 2008..In the UK it is recommended that acetylcholinesterase inhibitors be restricted to patients with moderate Alzheimer's disease, and progress monitored within specialist clinics...
- Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse modelStefan Waibel
Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
J Neurol 251:1080-4. 2004..Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS...
- Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeysS S Negus
Alcohol and Drug Abuse Research Center, Harvard Medical School McLean Hospital, Belmont, Massachusetts, USA
J Pharmacol Exp Ther 291:60-9. 1999..These findings suggest that although indatraline may decrease cocaine-taking behavior in rhesus monkeys, it also produces undesirable side effects that may limit its clinical utility in the treatment of cocaine dependence...
- Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchiE Naline
Research Unit EA220, Faculty of Medicine, Versailles University, Hospital Foch, Suresnes, France
Eur Respir J 29:575-81. 2007..3+/-8.8 and 14.6+/-3.7 min for formoterol and salbutamol, respectively. In isolated human bronchi, indacaterol behaved as a long-acting beta2-adrenoceptor agonist with high intrinsic efficacy and fast onset of action...
- Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's diseaseRachelle S Doody
Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas 77030, USA
Drugs Aging 25:163-74. 2008..Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD...
- Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transportersHan Yu
Laboratory of Medicinal Chemistry, Building 8, Room B1 23, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, 20892 0815, USA
J Med Chem 47:2624-34. 2004..Ex vivo autoradiography, however, demonstrated that iv administration of (-)-(1R,3S)-11 produced a dose-dependent, persistent occupation of 5-HT transporter binding sites but not DA transporter sites...
- Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezilYuki Takada-Takatori
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Doshisha Women s College, Kyoto, Japan
J Neurosci Res 86:3575-83. 2008..This study provides novel insight into the mechanism of donepezil-induced neuroprotection that involves nAChR up-regulation...
- A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 23:2194-201. 2008..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
- Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPDS Pascoe
Novartis Pharma AG, Basel, Switzerland
Int J Clin Pharmacol Ther 49:153-61. 2011..The 24-h bronchodilator effect and pharmacokinetics of indacaterol were also investigated...
- GHB: Discrimination and effects on learningLisa Baker; Fiscal Year: 2003..Behavior under these assays is sensitive to other abused drugs. Therefore, these assays may be of value in characterizing the effects of GHB. ..
- Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly SubjectsChristopher H van Dyck; Fiscal Year: 2010..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
- REGULATION OF SENESCENCE AND APOPTOSIS IN LYMPHOCYTESDennis Carson; Fiscal Year: 2004....
- DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PDC Olanow; Fiscal Year: 2003..abstract_text> ..
- Multiple Factors Affecting Placebo Response in PDChristopher Goetz; Fiscal Year: 2004..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
- Depression in Alzheimer's Disease Study 2 (DIADS-2)Lon Schneider; Fiscal Year: 2007..unreadable] [unreadable]..
- Predictors of Alzheimers Disease in Mild Cognitive ImpairmentOscar Lopez; Fiscal Year: 2007..g., structural and perfusion MRI, plasma beta-amyloid) and the factors that modify the risk to express the clinical syndrome takes on an added importance. [unreadable] [unreadable] [unreadable] [unreadable]..
- Light Treatment for Sleep/Wake Disturbances ADJerome Yesavage; Fiscal Year: 2008..Outcome will be documented by objective circadian activity rhythm parameters and standard sleep/wake measures both assessed by actigraphy. ..
- TREATMENTS FOR INSOMNIAJerome Yesavage; Fiscal Year: 2003..This five-year application will ultimately include 90 treatment subjects aged >60 years (three groups of 30 each). ..
- A Comprehensive Database of Cost-Effectiveness AnalysesPeter Neumann; Fiscal Year: 2003..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
- Substance Abuse in ADHD GirlsTimothy Wilens; Fiscal Year: 2006..Thus, the research, approach, and goals of this R01 application are consistent with those underscored in the PA and by the Institute of Medicine as being of the highest research priority. ..
- CDP-choline: Mechanisms in Cerebral IschemiaRAO ADIBHATLA; Fiscal Year: 2006..Arachidonic acid activates neutral sphingomyelinase, resulting in membrane disintegration. PCCT activity was stimulated by exogenous CDP-choline. Aim 2 will be tested in gerbil transient forebrain ischemia. ..
- AD CAREGIVER WELL-BEING COUNSELING/INSTITUTIONALIZATIONMary Mittelman; Fiscal Year: 2006..abstract_text> ..
- Southeastern Michigan Parkinson's Disease ProgramPeter LeWitt; Fiscal Year: 2006..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
- MEDICAL GOALS IN DEMENTIA: ETHICS & QUALITY OF LIFEPeter Whitehouse; Fiscal Year: 2005..In the final years of the proposal we will develop interventions based on the knowledge accumulated during the initial periods of the grant to enhance the decision- making of other caregiving units. ..
- Alzheimer's Disease Research Center ConferenceLeon Thal; Fiscal Year: 2006..Partial support is requested to defray travel costs of invited speakers and to provide travel awards to minority healthcare providers, junior faculty, postdocs and students. [unreadable] [unreadable] [unreadable]..
- SOCIAL FACTORS AND EPIDEMIOLOGY OF COGNITIVE DECLINEMarie Florence Shadlen; Fiscal Year: 2005..Hence, these projects will allow Dr Shadlen to achieve her 5-year goal of synthesis of her interests in racial differences, dementia, and epidemiology into an independent, thought-provoking research program. ..
- Safety and Efficacy of Sertraline for Depression Congestive Heart FailureRanga Krishnan; Fiscal Year: 2007..Information collected in these follow-up contacts will include deaths, re-hospitalizations, cardiac events, functional status/quality of life measures, and level of depressive symptoms. ..
- Creation and demonstration of a palliative care research cooperative groupJean S Kutner; Fiscal Year: 2010....
- Effects of Chemotherapy on Brain FunctionWilliam J Jagust; Fiscal Year: 2010..They are also relevant to the overall mission of the NIH because of the negative impact that cognitive dysfunction has on quality of life. ..
- Study on Thalidomide as BACE1 inhibitor in Alzhiemer's diseaseMarwan N Sabbagh; Fiscal Year: 2010..We propose that Thalidomide may represent a BACE1 inhibitor. ..
- Parenteral Hydration in Advanced Cancer Patients: A Randomized Controlled TrialEduardo Bruera; Fiscal Year: 2009..In this study, we will test if giving fluid through the vein will improve the symptoms, delay confusion and prolong life in patients who are no longer to drink at the end of life. ..
- Juvenile Bipolar Disorder and Substance AbuseTimothy E Wilens; Fiscal Year: 2010..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
- Siblings With Ischemic Stroke Study (SWISS)JAMES MESCHIA; Fiscal Year: 2009..DNA banking and the creation of permanent lymphoblastoid cell lines will be done to permit future collaborative efforts to study the genetic basis for stroke risk. ..
- Glycine Transport Inhibition for Nicotine Dependence in SchizophreniaA Evins; Fiscal Year: 2009....
- Amyloid Imaging in Frontotemporal Dementia and Alzheimer's DiseaseWilliam Jagust; Fiscal Year: 2009..PIB could become a diagnostic tool that is useful in diagnosing AD and FTLD during life. This will be especially important as new treatments for both disorders are developed. ..
- CNS Mechanisms that Modulate RewardKENNETH CARR; Fiscal Year: 2008..The research proposed in this application is aimed at elucidating midbrain and striatal mechanisms involved in the increased behavioral responsiveness of FR rats to drugs of abuse. ..
- Donepezil-enhanced management of delirium in aged hip fracture patientsEdward Marcantonio; Fiscal Year: 2007..This study is the first in the PI's long-term goal to better understand the pathophysiological mechanisms of delirium and to develop and test therapies targeted to address these mechanisms. [unreadable] [unreadable] [unreadable]..
- DEMENTIA AND PSYCHIATRIC DISORDERS IN ASSISTED LIVINGAdam Rosenblatt; Fiscal Year: 2007..abstract_text> ..
- Treating Mildly Cognitive- Impaired Depressed ElderlyGregory Pelton; Fiscal Year: 2005....
- Alzheimer's Disease in Down Syndrome: Antioxidant TrialIra Lott; Fiscal Year: 2005..The pilot trial should also contribute information as to the possible role of antioxidants in the treatment or prevention of AD in the general population. ..
- Treating Agitation/Psychosis in Dementia/ParkinsonismRoger Kurlan; Fiscal Year: 2004..This study will provide important information regarding the optimal treatment of psychosis and agitation for patients with the commonly encountered combination of primary dementia and parkinsonism. ..
- POLYAMINE INVOLVEMENT IN MAMMARY CARCINOGENESISAndrea Manni; Fiscal Year: 2001....
- Third Symposium Cell Volume & Signalling RegulationPETER LAUF; Fiscal Year: 2003..This meeting's success on U.S. soil will foster continuation of gathering of high-caliber scientists at subsequent international meetings ..
- Neuropeptide Y for Cancer-Associated AnorexiaAminah Jatoi; Fiscal Year: 2003..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
- Pioglitazone in Alzheimer's Disease ProgressionDavid Geldmacher; Fiscal Year: 2003..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
- Nocardia: A Novel Environmental Agent For Parkinsonism?Peter LeWitt; Fiscal Year: 2003..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
- CANCER RESEARCH TRAINING IN NUCLEAR MEDICINEDavid Kuhl; Fiscal Year: 2003..The combination of faculty motivation, structured curricula, excellent facilities, and superb intellectual environment is expected to prepare individuals to be tomorrow's leaders in cancer research. ..
- DEPRESSION IN ELDERLY CARDIAC PATIENTSRanga Krishnan; Fiscal Year: 2003....
- PREVENTION OF SUICIDE IN OLDER PRIMARY CARE PATIENTSCharles Reynolds; Fiscal Year: 2002..Data will also be collected to document the impact of intervention on patient care, and on physician knowledge, attitudes, and satisfaction and test hypothesis derived from preliminary studies of the three IRCs. ..
- FUNCTIONAL BRAIN IMAGING WITH RNA REDISTRIBUTION ANALYSICarol Barnes; Fiscal Year: 2002..Our long-term goal is to create a novel image analysis tool that links behavioral systems, and molecular neuroscience approaches to a variety of behaviors and brain regions. ..
- Mode of Action of Insecticides: ElectrophysiologicalToshio Narahashi; Fiscal Year: 2004..This information will significantly contribute to the development of newer therapeutic means of insecticide intoxication of humans and of more effective and safer insecticides. ..
- LUNG HEALTH STUDY--LONG TERM FOLLOW UPDonald Tashkin; Fiscal Year: 2002..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
- Polyamines and Breast Cancer BiologyAndrea Manni; Fiscal Year: 2005..The ultimate goal of these studies is to identify critical signaling molecules which can be targeted in conjunction with antipolyamine therapy to optimize prevention of metastasis from breast cancer. ..
- Effects of Androgens and Cannabinoids on LearningSTUART LEONARD; Fiscal Year: 2005..These results will provide, for the first time, information regarding the interactive effects of testosterone and THC on cognitive behavior. ..
- CI Therapy and Novel Virtual EnvironmentsCarolee Winstein; Fiscal Year: 2005..Phase II will establish a broader application in the clinical environment, incorporate patient perspectives, and longer-term outcomes. ..
- Treatment Outcomes of Vascular DepressionPUDUGRAMAM DORAISWAMY; Fiscal Year: 2005..The proposed trial will provide information of value to the practitioner and also provide data to build a more comprehensive model of the prognostic impact of frontal-subcortical brain changes on the outcome of late-life depression. ..
- GENE THERAPY OF BASAL FOREBRAIN CHOLINERGIC LESIONSLeon Thal; Fiscal Year: 2004..These approaches will not only be applicable for AD, but other neurodegenerative disorders and for delivering other transgenes of interest. ..
- PANDAS and Strep Infection: Are they Linked?Roger Kurlan; Fiscal Year: 2004..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..
- QBP1 Mimetics as Therapeutics for Huntington's DiseaseJames Burke; Fiscal Year: 2004..Testing a small number of mimetics for efficacy and toxicity in mouse models of polyglutamine repeat disease will be the subject of a later grant application. ..
- Distal Lung Inflammation Effect on Asthma ExacerbationsDonald Tashkin; Fiscal Year: 2008..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
- Improving memory after hippocampal cell lossMARK BARDGETT; Fiscal Year: 2007..The results may shed light on new directions in the treatment of memory disorders, and the proposed work will also enhance education in biomedical research among college undergraduates in Kentucky. [unreadable] [unreadable] [unreadable]..
- Metabolic Measures of Tissue DamageRobert Bartha; Fiscal Year: 2005..abstract_text> ..
- Methylphenidate for Fatigue in Advanced Cancer PatientsEduardo Bruera; Fiscal Year: 2009....
- RISK MARKERS FOR DEMENTIA AFTER STROKEDavid Nyenhuis; Fiscal Year: 2004..They state that refinement in our knowledge of mechanisms and causes for dementia in stroke patients may lead to an improvement in prevention and treatment strategies. ..
- Dementia of Parkinson Type: Clinicopathologic PhenotypeJames Galvin; Fiscal Year: 2004..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..
- Development of Inventory of Depressive SymptomatologyPUDUGRAMAM DORAISWAMY; Fiscal Year: 2005..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
- Brain and Behavior Correlates of Arm RehabilitationCarolee Winstein; Fiscal Year: 2004..abstract_text> ..
- Morphine versus Methadone as First Line Strong Opioid for Cancer PainEduardo Bruera; Fiscal Year: 2009..Relevance to Public Health: In this study, we will test if methadone is better than morphine in cancer pain control, quality of life, and is more cost-effective. ..
- Validation of the NINDS VCI Neuropsychology ProtocolsDavid Nyenhuis; Fiscal Year: 2009..Reliable and valid VCI neuropsychology test protocols are a necessary first step to improved diagnostic criteria and a better understanding of both the mechanisms of VCI and the development of new treatment options. ..
- Palliative Oxygen for the Relief of BreathlessnessAmy Abernethy; Fiscal Year: 2007..The results will also advance a long-standing international debate about the role of palliative oxygen for intractable dyspnea and it's funding. [unreadable] [unreadable] [unreadable]..
- Alzheimer's Diagnosis by Real-Time Motion Corrected FMRIClifford Jack; Fiscal Year: 2004..Aim number 4: to assess motion corrected fMRI as a diagnostic test for early Alzheimer's disease. ..